Daniel T. Scavilla - 04 Mar 2026 Form 4 Insider Report for DENTSPLY SIRONA Inc. (XRAY)

Reporting relationship: President, CEO & Member of BOD, Director
Issuer ticker: XRAY
Reported as of: 04 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Mar 2026, 17:25:07 UTC
Prior SEC filing: 26 Feb 2026
Next SEC filing: 12 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Jessica Nielsen Causey, Attorney-in-Fact for Daniel T. Scavilla

Key filing fact

Daniel T. Scavilla filed Form 4 for DENTSPLY SIRONA Inc. (XRAY) on 06 Mar 2026.

Key facts

This page summarizes Daniel T. Scavilla's Form 4 filing for DENTSPLY SIRONA Inc. (XRAY).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 06 Mar 2026, 17:25.

Change

Previous filing in this sequence was filed on 26 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001642439 Primary reporting owner

Scavilla Daniel T

Relationship: President, CEO & Member of BOD, Director
Address: C/O DENTSPLY SIRONA INC, 13320-B BALLANTYNE CORPORATE PLACE, CHARLOTTE
Signature: /s/ Jessica Nielsen Causey, Attorney-in-Fact for Daniel T. Scavilla
Signature date: 06 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

XRAY transaction

Common Stock

Award

Transaction value
Shares: +145,089
Change %: +866%
Price: $0.000000^*
Shares after: 161,839
Date: 04 Mar 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

XRAY transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +2,066,600
Change %
Price: $0.000000^*
Shares after: 2,066,600
Date: 04 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,066,600
Exercise price: $15.46
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Award consists entirely of Restricted Stock Units (RSUs) which vest in annual one-third (1/3) increments over a three-year (3) period ending March 4, 2029.

Footnote F2

Stock options vest in annual one-third (1/3) increments over a three-year (3) period ending March 4, 2029, with an exercise price equal to 115% of the closing price of the Issuer's common stock as of the date of grant.